Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

64.65 +6.07 (+10.36%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 20.2% in the afternoon session after the company reported strong first quarter 2025 results which significantly beat analysts'... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Hims & Hers Stock Popped Tuesday, but Eli Lilly and Novo Nordisk Dropped
Good news for Hims & Hers stock spooks Lilly and Novo investors. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Which stocks are most active on Tuesday?
These stocks are making the most noise in today's session. Stay tuned for the latest updates! 
Via Chartmill
Earnings Scheduled For May 5, 2025
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
HIMS Q1 Earnings Call: Personalized Care and New Partnerships Drive Upside, Guidance Signals Near-Term Transition
Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q1 CY2025, with sales up 111% year on year to $586 million. Revenue guidance for the full year exceeded... 
Via StockStory
Hims & Hers Stock Rises on Fundamentals and Squeeze Potential
Hims & Hers stock is now giving investors another reason to consider it a buy for the coming months, as the latest quarterly earnings show momentum. 
Via MarketBeat
What's Going On With Hims & Hers Stock Tuesday?
Hims & Hers stock was trading lower but has since reversed and began trading higher after the company reported first-quarter earnings on Monday after the market closed. 
Via Benzinga
Looking At Hims & Hers Health's Recent Unusual Options Activity
Via Benzinga
FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Top 1% Stock, Hims & Hers Health, Dives On Lackluster Outlook
The company recently inked a deal with Novo Nordisk. But will that bolster current-quarter sales? 
Via Investor's Business Daily
Hims & Hers Stock Slides Pre-Market As Q2 Sales View Misses Estimates, But Retail Traders Shrug It Off
Its second-quarter revenue guidance of $530 million-$550 million fell short of the $564.57 million consensus estimate. 
Via Stocktwits
Topics Earnings
Exposures Financial
Hims & Hers Health’s (NYSE:HIMS) Q1: Beats On Revenue, Full-Year Outlook Slightly Exceeds Expectations
Telehealth company Hims & Hers Health (NYSE:HIMS) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 111% year on year to $586 million. Revenue guidance for the full... 
Via StockStory
Hims & Hers Health Q1 Earnings: Revenue Jumps 111%, Subscribers Up 38%, Q2 Guidance Falls Short Of Estimates, Shares Slide
Hims & Hers Health reports first-quarter revenue of $586.01 million, beating estimates of $538.2 million, according to Benzinga. 
Via Benzinga
ETFs Last Week: Tech-Fueled Rally Powers Gains During Trade Optimism
Wall Street rebounds from tariff losses, with S&P 500 recording second consecutive weekly gain. Top performers were tech giants and leveraged ETFs. 
Via Benzinga
Topics ETFs Stocks World Trade
Exposures Tariff US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Hims & Hers Names New COO. Stock Rallies.
Hims stock rose Monday after the telehealth program named technology industry veteran Nader Kabbani as its new chief operating officer. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Hims & Hers Appoints Ex-Amazon Exec Ahead Of Q1 Results
Hims & Hers Health shares are trading marginally lower Monday morning. The company earlier appointed Nader Kabbani as its new Chief Operations Officer, ahead of Q1 results. 
Via Benzinga
Hims & Hers: The Next Amazon? Novo Nordisk Might Be Prime Delivery
Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to expand into other healthcare areas. 
Via Benzinga
Hims & Hers Appoints Amazon Veteran Nader Kabbani COO To Support Expansion
A nearly 20-year Amazon veteran, Nader Kabbani said he was drawn to Hims & Hers by its potential to expand access to fast, reliable, and high-quality care. 
Via Stocktwits
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence COVID-19 Interest Rates
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them? 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Hims & Hers Health Earnings: What To Look For From HIMS
Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting results tomorrow after the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Is Novo Nordisk Stock Trading Higher On Friday?
Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease affecting patients with obesity. 
Via Benzinga
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors. 
Via The Motley Fool
Topics World Trade
Exposures Tariff
CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment
Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access initiatives. 
Via Benzinga
Where Is Hims & Hers Stock Headed After Wegovy Tie-Up? Retail Traders Bet On Rebound To Over 2-Month High
Needham called the tie-up a “groundbreaking partnership” and said it alleviates investor concerns around Hims’ ability to hit its 2025 weight loss revenue guidance. 
Via Stocktwits
Exposures Product Safety
Hims & Hers Stock Soars on Novo Nordisk Collaboration
Hims & Hers stock rallies by over 25% on news of a collaboration with Novo Nordisk and its weight loss flagship products, and that's not all. 
Via MarketBeat
Most active stocks in Tuesday's session
Discover the most active stocks in Tuesday's session. Stay informed about the stocks that are generating the most trading volume! 
Via Chartmill
Why Hims & Hers Health and LifeMD Are Skyrocketing Today
Via The Motley Fool
Topics Stocks
Exposures US Equities
Hims & Hers Health (HIMS) Shares Skyrocket, What You Need To Know
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 34.9% in the pre-market session after Novo Nordisk announced plans to offer its weight loss drug Wegovy through the company's (Hims &... 
Via StockStory
Topics Economy Government World Trade
Exposures Economy Interest Rates Political
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback